GILD Gilead Sciences, Inc.

$GILD OCT30 160C · still actionable Zone: $152.00 to $154.14 Invalidation: close under $150 Objectives: $160.51, then $170 The math: up 4.9% to the first objective and 11.1% to the second, against 2.0% risk on the invalidation, better than 5 to 1 to the second Dear friend, picture a swing setup where a strong stock took a step back on Monday and landed on solid ground. Gilead closed at $153.07, down 2.0 percent on the day, after buyers held the $152.92 low well above the $150 round number, which means the pullback stopped where support should matter most. Earnings on October 29 give this move a clear test, and what that means for you is simple. If price can reclaim ground toward the $160.51 high from last week, the dip will look like rest rather than damage. P.S. Watch the $150 line on a closing basis. A close below it changes the whole story, and a hold above it keeps the path back to $160.51 open.

$GILD decade long base breakout and retest here in 2026. Seems so straight foward and simple this year doesn't it lol.

Wait a second, this is the $GILD story beyond HIV you kept asking for? Emvistegrast in Phase 2 SWIFT, moderate to severe ulcerative colitis 66 percent clinical response at 12 weeks vs 37 percent on placebo 31 percent remission vs 8 percent Tolerability comparable to placebo, no serious effects linked to the drug, and Phase 3 monotherapy is planned for 2027 A pill for a pathway doctors already trust (yes, that convenience part is the whole pitch) So is this actually the second act?

$GILD OCT30 160C · still actionable Zone: $155.10 to $157.28 Invalidation: close under $150 Objectives: $160.51, then $175 The math: up 2.8% to the first objective and 12.0% to the second, against 4.0% risk on the invalidation, about 3 to 1 to the second Dear friend, think of this swing setup like a house resting on the highest ground on its street instead of sliding back down. Gilead closed Friday at $156.19, up 3.3 percent in five sessions, after buyers pushed price to $160.51 on Thursday, the highest price in a year, and held the $155.62 low on Friday. Earnings on October 29 give buyers a clear date to work toward, with the October 30 calls right after that report, and a close under $150 would mean the story is wrong. P.S. Watch $160.51 on Monday. A close over that yearly high would show buyers pushing, not just resting.

The daily tells you when. The weekly tells you if. $GILD held 2% above its July shelf during a -7.5% pullback and never reached the 30-week line — then new highs. $MU bounces keep failing inside a weekly that broke in June. Bigger chart always wins. Educational, not advice

$GILD - Stock consolidating on the weekly time frame and making cup shaped pattern. Swing calls added in the group. Looking for a bigger breakout above $155 for a move towards $165 and $180. high watch going into next few weeks. Recent news - Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens

$GILD comes up Strong at a 16 on the quality momentum scanner right now, 8th of 259 in Biotech

$GILD A new multi-program collaboration and license agreement with Vir Biotechnology announced on October 14, 2026. Though the collaboration is the clear catalyst for today’s move. Volume has been lighter than average. If it were stronger it would of been over $154.98. But who's complaining.

$GILD preparing for the breakout. it had a ton of crazy runs in the past, why not another one

$GILD so when will this old compamy finally make a 30 USD/share offering for Kyverna to stay to date with modern medicine?

$GILD a strategic acquisition like Kyverna t cell immnutherapy would make me more bullish about this dying star